Literature DB >> 9854079

Influence of incubation time, inoculum size, and glucose concentrations on spectrophotometric endpoint determinations for amphotericin B, fluconazole, and itraconazole.

M H Nguyen1, C Y Yu.   

Abstract

We addressed the influence of the incubation time (24 h versus 48 h), starting inoculum size (standard inoculum size, approximately 10(3) CFU/ml, versus large inoculum size, approximately 10(4) CFU/ml), and supplementation with 2% glucose of RPMI 1640 medium on the spectrophotometric determination of the MICs of amphotericin B, fluconazole, and itraconazole. We compared the MICs determined spectrophotometrically with those determined by the standard broth macrodilution method (National Committee for Clinical Laboratory Standards approved guideline M27-A). The agreement between the results of the spectrophotometric and standard methods for amphotericin B testing was 100%; this agreement was independent of the inoculum size and incubation time. On the other hand, the agreement for the results for fluconazole testing and itraconazole testing was dependent on the inoculum size and incubation time. With large inoculum size, excellent agreement can be achieved at 24 h. With standard inoculum size, acceptable agreement can be achieved only at 48 h. In contrast to previous observations, the addition of 2% glucose did not have any significant impact on the growth density at 24 h, nor did it improve the agreement with the standard method. Furthermore, supplemental glucose might falsely elevate the MIC at 48 h.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9854079      PMCID: PMC84190     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  16 in total

1.  Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests.

Authors:  A Espinel-Ingroff; C W Kish; T M Kerkering; R A Fromtling; K Bartizal; J N Galgiani; K Villareal; M A Pfaller; T Gerarden; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

2.  In vitro studies of activities of some antifungal agents against Candida albicans ATCC 10231 by the turbidimetric method.

Authors:  M T Blanco; C Pérez-Giraldo; J Blanco; F J Morán; C Hurtado; A C Gómez-García
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

3.  Comparison of visual and spectrophotometric methods of MIC endpoint determinations by using broth microdilution methods to test five antifungal agents, including the new triazole D0870.

Authors:  M A Pfaller; S A Messer; S Coffmann
Journal:  J Clin Microbiol       Date:  1995-05       Impact factor: 5.948

Review 4.  Antifungal susceptibility testing.

Authors:  J H Rex; M A Pfaller; M G Rinaldi; A Polak; J N Galgiani
Journal:  Clin Microbiol Rev       Date:  1993-10       Impact factor: 26.132

5.  Comparative evaluation of alternative methods for broth dilution susceptibility testing of fluconazole against Candida albicans.

Authors:  M A Pfaller; C Grant; V Morthland; J Rhine-Chalberg
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

6.  Defining conditions for microbroth antifungal susceptibility tests: influence of RPMI and RPMI-2% glucose on the selection of endpoint criteria.

Authors:  J L Rodriguez-Tudela; J V Martinez-Suárez
Journal:  J Antimicrob Chemother       Date:  1995-06       Impact factor: 5.790

7.  Turbidimetric and visual criteria for determining the in vitro activity of six antifungal agents against Candida spp. and Cryptococcus neoformans.

Authors:  F Barchiesi; M Del Poeta; V Morbiducci; F Ancarani; G Scalise
Journal:  Mycopathologia       Date:  1993-10       Impact factor: 2.574

8.  Antifungal susceptibility testing of yeasts: evaluation of technical variables for test automation.

Authors:  F C Odds; L Vranckx; F Woestenborghs
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

9.  Comparative study of broth macrodilution and microdilution techniques for in vitro antifungal susceptibility testing of yeasts by using the National Committee for Clinical Laboratory Standards' proposed standard.

Authors:  F Barchiesi; A L Colombo; D A McGough; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

10.  Improved medium for fluconazole susceptibility testing of Candida albicans.

Authors:  J L Rodriguez-Tudela; J V Martinez-Suarez
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191

View more
  13 in total

1.  Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp.: NCCLS collaborative evaluation. National Committee for Clinical Laboratory Standards.

Authors:  A Espinel-Ingroff; M Bartlett; V Chaturvedi; M Ghannoum; K C Hazen; M A Pfaller; M Rinaldi; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

2.  Multicenter comparison of the VITEK 2 antifungal susceptibility test with the CLSI broth microdilution reference method for testing amphotericin B, flucytosine, and voriconazole against Candida spp.

Authors:  M A Pfaller; D J Diekema; G W Procop; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2007-10-03       Impact factor: 5.948

3.  Influence of glucose supplementation and inoculum size on growth kinetics and antifungal susceptibility testing of Candida spp.

Authors:  M Cuenca-Estrella; T M Díaz-Guerra; E Mellado; J L Rodríguez-Tudela
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

4.  Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada.

Authors:  G St-Germain; M Laverdière; R Pelletier; A M Bourgault; M Libman; C Lemieux; G Noël
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

5.  International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole.

Authors:  A Espinel-Ingroff; F Barchiesi; M Cuenca-Estrella; M A Pfaller; M Rinaldi; J L Rodriguez-Tudela; P E Verweij
Journal:  J Clin Microbiol       Date:  2005-08       Impact factor: 5.948

6.  Comparison of visual 24-hour and spectrophotometric 48-hour MICs to CLSI reference microdilution MICs of fluconazole, itraconazole, posaconazole, and voriconazole for Candida spp.: a collaborative study.

Authors:  A Espinel-Ingroff; F Barchiesi; M Cuenca-Estrella; A Fothergill; M A Pfaller; M Rinaldi; J L Rodriguez-Tudela; P E Verweij
Journal:  J Clin Microbiol       Date:  2005-09       Impact factor: 5.948

7.  Comparative evaluation of a new fluorescent carboxyfluorescein diacetate-modified microdilution method for antifungal susceptibility testing of Candida albicans isolates.

Authors:  Robert S Liao; Robert P Rennie; James A Talbot
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

8.  Analysis of the influence of Tween concentration, inoculum size, assay medium, and reading time on susceptibility testing of Aspergillus spp.

Authors:  Alicia Gomez-Lopez; Amel Aberkane; Eva Petrikkou; Emilia Mellado; Juan Luis Rodriguez-Tudela; Manuel Cuenca-Estrella
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

9.  Comparison of visual and spectrophotometric methods of broth microdilution MIC end point determination and evaluation of a sterol quantitation method for in vitro susceptibility testing of fluconazole and itraconazole against trailing and nontrailing Candida isolates.

Authors:  Beth A Arthington-Skaggs; Wendy Lee-Yang; Meral A Ciblak; Joao P Frade; Mary E Brandt; Rana A Hajjeh; Lee H Harrison; Andre N Sofair; David W Warnock
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

10.  Role for cell density in antifungal drug resistance in Candida albicans biofilms.

Authors:  Palani Perumal; Satish Mekala; W LaJean Chaffin
Journal:  Antimicrob Agents Chemother       Date:  2007-05-14       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.